ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 609,40
0,50%
Dow Jones
38 778,10
0,00%
DAX
18 113,18
0,22%
Brent Oil
83,705
-0,23%
Bitcoin
65 243,96
-1,87%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Verve Therapeutics Inc (VERV)

  7. Verve Therapeutics Inc (VERV) Actualités

VERV Verve Therapeutics Inc

5,5048
0,2348 (4,46%)
Avant marché
Dernière mise à jour : 14:15:52
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Verve Therapeutics Inc VERV NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,2348 4,46% 5,5048 14:15:52
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
5,27
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
07/6/202422:07EDGAR2Form 8-K - Current report
31/5/202422:01GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
31/5/202413:14EDGAR2Form 8-K - Current report
31/5/202413:00GLOBEVerve Therapeutics Announces Leadership Update
30/5/202422:01GLOBEVerve Therapeutics to Participate in Upcoming Investor..
08/5/202413:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202413:15EDGAR2Form 8-K - Current report
08/5/202413:00GLOBEVerve Therapeutics Announces Pipeline Progress and Reports..
07/5/202413:00GLOBEVerve Therapeutics Announces Dosing of First Patient in..
03/5/202422:01GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
02/4/202413:00GLOBEVerve Therapeutics Announces Updates on its PCSK9 Program
28/3/202421:51GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
01/3/202422:01GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
27/2/202414:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202414:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:45EDGAR2Form 8-K - Current report
27/2/202413:30GLOBEVerve Therapeutics Provides Pipeline Progress and Reports..
16/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202412:30GLOBEVerve Therapeutics to Participate in the Guggenheim..
02/1/202412:30GLOBEVerve Therapeutics to Present at the 42nd Annual J.P. Morgan..
01/12/202322:00GLOBEVerve Therapeutics Announces Closing of Public Offering of..
29/11/202322:54EDGAR2Form 8-K - Current report
29/11/202322:47EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/11/202312:47DJNVerve Therapeutics Shares Tumble Premarket After Stock Sales
29/11/202304:37GLOBEVerve Therapeutics Announces Pricing of Public Offering of..
28/11/202322:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/11/202322:01GLOBEVerve Therapeutics Announces Proposed Public Offering of..
13/11/202312:34EDGAR2Form 8-K - Current report
12/11/202321:30GLOBEVerve Therapeutics Announces Interim Data for VERVE-101..
07/11/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:00EDGAR2Form 8-K - Current report
07/11/202312:30GLOBEVerve Therapeutics Highlights Recent Company Progress and..
31/10/202311:59DJNBeam Therapeutics to Sell Rights in Verve Licensing Deal to..
31/10/202311:01GLOBEVerve and Lilly Relationship Expands to Include Verve’s In..
23/10/202313:22DJNVerve Therapeutics Gets Clinical Hold For VERVE-101 Lifted..
23/10/202312:41EDGAR2Form 8-K - Current report
23/10/202312:30GLOBEVerve Therapeutics Announces Clearance of Investigational..
26/9/202312:30GLOBEVerve to Present Interim Data from the heart-1 Phase 1b..
21/9/202322:05GLOBEVerve Therapeutics to Participate in the 2023 Cantor Global..
18/9/202312:30GLOBEVerve Expands Leadership Team with Appointment of Frederick..
10/8/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:00EDGAR2Form 8-K - Current report
10/8/202312:30GLOBEVerve Therapeutics Highlights Recent Company Progress and..
03/8/202312:30GLOBEVerve Therapeutics to Present at the Canaccord 43rd Annual..

Dernières Valeurs Consultées

NASDAQ
VERV
Verve Therapeutics
TG
19X
Axsome Therapeutics
USOTC
TLTZF
Tele2 Ab (PK)
NASDAQ
LIAUX
LifeX Inflation-Protecte...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés